This inventor holds 1 USPTO granted patent. Top assignee: Sanofi-Aventis. Active years: 2006.
Company Filing History:
Years Active: 2006
Title: Sabrina Obert: Innovator in Pharmaceutical Chemistry
Introduction
Sabrina Obert is a notable inventor based in Sommières, France. She has made significant contributions to the field of pharmaceutical chemistry, particularly through her innovative work on phenylethanolamine compounds. Her research has led to advancements in medicinal formulations that can benefit various therapeutic applications.
Latest Patents
Sabrina Obert holds a patent for a crystalline form of phenylethanolamine, specifically titled "Crystalline form of phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same." This invention pertains to the B form of ethyl [(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethylamino]-5,6,7,8-tetrahydronaphth-2-yloxy]acetate hydrochloride. The compound is recognized for its potential use as a medicament, exhibiting unique physical characteristics. The product can be obtained through salification of the base or by recrystallization of the salt from an alcohol.
Career Highlights
Sabrina Obert is currently associated with Sanofi-Aventis, a leading global biopharmaceutical company. Her role at the company allows her to engage in cutting-edge research and development, contributing to the advancement of pharmaceutical sciences. With her expertise, she plays a crucial part in the innovation of new therapeutic solutions.
Collaborations
Throughout her career, Sabrina has collaborated with esteemed colleagues, including Isabelle Ziri and Olivier Monnier. These partnerships have fostered a collaborative environment that enhances the research and development process, leading to impactful innovations in the pharmaceutical industry.
Conclusion
Sabrina Obert's contributions to pharmaceutical chemistry exemplify the importance of innovation in medicine. Her patent on phenylethanolamine compounds showcases her commitment to advancing healthcare solutions. Through her work at Sanofi-Aventis and collaborations with fellow researchers, she continues to make strides in the field, ultimately benefiting patients worldwide.